Please login to the form below
ASH
This page shows the latest ASH news and features for those working in and with pharma, biotech and healthcare.
bluebird bio shares therapy updates for 2022
At the 63rd ASH Annual Meeting, bluebird bio revealed new data demonstrating that adult and paediatric patients diagnosed with β-thalassaemia, who require regular RBC transfusions, can produce normal or
Latest news
-
Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
Roche will present a slew of new data at the American Society of Hematology’s (ASH) annual meeting next month, showcasing new immunotherapies, treatment combinations, novel endpoints and fixed-duration regimens ... Our data at ASH reinforces our
-
ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more
A round-up of some of the key data from the annual American Society of Hematology (ASH) meeting. ... bluebird bio also posted long-term data for its own beta thalassaemia gene therapy Zynteglo (betibeglogene autotemcel) at ASH 2020.
-
bluebird bio’s beta thalassaemia gene therapy Zynteglo scores promising long-term data
Results presented at annual American Society of Haematology (ASH) meeting. bluebird bio has revealed some long-term data for its gene therapy betibeglogene autotemcel, which is marketed as Zynteglo in the ... bluebird bio announced the new long-term data
-
Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib
CML). The detailed results, presented at the annual American Society of Hematology (ASH) meeting, come from the phase 3 ASCEMBL study.
-
Gilead swoops on Forty Seven with $4.9bn all-cash deal
Magrolimab (formerly Hu5F9-G4) generated positive results in a phase 1b study reported at the ASH conference in the US in December, which revealed a 92% overall response rate – including 50%
More from news
Approximately 13 fully matching, plus 69 partially matching documents found.
Latest Intelligence
-
The importance of beliefs in creative health engagement
By Ash Rishi. The world changed in 2020. I don’t need to explain how. ... Ash Rishi is CEO and Co-Founder of COUCH Health. 29th June 2022.
-
A creative awakening – how pharma is bringing innovation to the patient journey
observed Ash Rishi, co-founder of creative health engagement agency COUCH Health.
-
Patient diversity in clinical trials needs to be centre stage
It is a promising start but Ash Rishi, co-founder of patient engagement agency COUCH Health, witnesses a consistent lack of diversity across ethnicity, gender, age and socio-economic status in
-
Why we need to look beyond cultural competency to fix the patient diversity challenge
By Ash Rishi. The healthcare industry has work to do. There is a known implicit bias in healthcare, which has been shown to influence treatment decisions, adherence and patient health outcomes. ... Ash Rishi is CEO and Co-Founder of COUCH Health.
-
Could coronavirus re-shape learning and development in pharma?
By Yvonne Ash. No company could have planned for the impact of coronavirus on safeguarding employees while ensuring business continuity and the need to adapt to a virtual environment.We have ... Yvonne Ash is Vice President, Learning Solutions at Syneos
More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.
Latest appointments
-
COUCH Health taps Mark Duman for chief strategy officer role
We’re thrilled to welcome Mark to COUCH Health. I’ve always been inspired by his energy and enthusiasm for everything that he works on,” commented Ash Rishi, chief executive officer
-
Publicis Health UK bolsters leadership team
Ash Kuchel, global group president of Publicis Health, said: “With her infectious passion and vision, Victoria was the perfect person for the job.
-
COUCH names Jenny McParland as account executive
Ash Rishi, COUCH's managing director, said: “We are proud to welcome Jenny to our team and excited to introduce her to our range of healthcare accounts.
-
Two new hires at Couch
Ash Rishi, also co-managing director at Couch, said: “The fact that they both have industry experience is a huge plus, but their experience of working with big brands such as
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Digital technologies: Pharma’s answer to achieving net zero emissions?
various degrees of ash and smoke for most of July and August.
-
#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
If you’re interested in getting involved in our mission to Demand Diversity, get in touch at ash@demanddiversity.co.
-
COUCH Health Engages Mark Duman as Chief Strategy Officer
Mark will report directly to CEO Ash Rishi. “It has been exciting to watch COUCH Health mature in recent years and firmly establish itself in the industry. ... COUCH Health CEO Ash Rishi added: “We’re thrilled to welcome Mark to COUCH Health.
-
COUCH Health Explores Lack of Ethnic Minorities in U.S. Clinical Trials
W ithout attracting diverse participant groups in clinical studies, we can’t be confident about how new treatments will work in the general population,” said CEO Ash Rishi. ... As our research shows, the barriers stopping ethnic minorities from
-
Should diversity in clinical trials be mandatory?
But going back to “what would mandatory look like?”, Ash believes we should have diversity benchmarks per disease area. ... Ash agreed with this approach, explaining that the engagement model in clinical trials is evolving.
More from PMHub
Approximately 2 fully matching, plus 16 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- Create Health Showreel
- AstraZeneca acquires TeneoTwo in a deal worth up to $1.27bn
- Cancer Research UK urges government to realise ‘science superpower’ ambitions as new report highlights ‘huge’ economic value
- Novartis UK launches first health-tech investor partnership to address cardiovascular care
- UK government invests £175m to ‘supercharge’ clinical research
- A creative awakening – how pharma is bringing innovation to the patient journey
- European Commission approves potential new treatment for Pompe disease
- Sanofi Global Health unveils new nonprofit Impact brand
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Novartis UK launches first health-tech investor partnership to address cardiovascular care
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
